- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
- Cancer847
- Pathology798
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
- Cancer847
- Pathology798
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- EGFR positive
- PD-L1 negative
- PR positive
- EGFR negative
- KRAS positive
- ALK negative
- ER negative
- PR negative
- BRAF positive
- ALK positive
- CD20 positive
- BRAF negative
- BRCA1 positive
- p16 positive
- BRCA2 positive
- ROS1 negative
- HLA positive
- MET positive
- MYC positive
- HLA-A positive
- IDH positive
- PIK3CA positive
- ROS1 positive
- p16 negative
- RET positive
- BCL2 positive
- CD19 positive
- HR positive
- TP53 positive
- dMMR positive
- IDH negative
- MSI-H positive
- NRAS positive
- BCL6 positive
- HPV negative
- MET negative
- MSS positive
- KRAS negative
- NF1 positive
- TP53 negative
- ANA positive
- BCR-ABL1 positive
- MSI-H negative
- NTRK positive
- PALB2 positive
- RET negative
- ctDNA positive
- dMMR negative
- BRCA positive
- CCND1 positive
- CD5 positive
- Ex19del positive
- HBsAg positive
- HLA negative
- HPV positive
- L858R positive
- anti-dsDNA positive
- BRCA1 negative
- COL7A1 positive
- FGFR2 positive
- HLA-A negative
- HRAS positive
- MGMT negative
- NTRK negative
- PTEN positive
- RB1 positive
- T790M positive
- TTR positive
- ABCA4 positive
- BRCA2 negative
- CFTR positive
- CLDN18.2 positive
- DLL3 positive
- FLT3 positive
- MDM2 positive
- MMR negative
- MMR positive
- NRAS negative
- RAS positive
- RB1 negative
- TROP2 negative
- TROP2 positive
- pMMR positive
- APOL1 positive
- APP positive
- BRCA negative
- C5 positive
- CD23 positive
- EBV positive
- FGFR3 positive
- FLT3 negative
- FMR1 positive
- G719X positive
- GPC3 positive
- JAK2 positive
- KIT positive
- Ki-67 positive
- L861Q positive
- MGMT positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MTAP positive
- NF2 positive
- NPM1 positive
- PMS2 positive
- PSEN1 positive
- PSEN2 positive
- Philadelphia chromosome negative
- Philadelphia chromosome positive
- PiZZ positive
- RAS negative
- RF positive
- RHO positive
- S768I positive
- UGT1A1 positive
- p53 positive
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- AGXT positive
- AKT negative
- AKT1 positive
- ALPL positive
- ATM positive
- Aβ1-42 positive
- CCND1 negative
- CCNE1 positive
- CD19 negative
- CD20 negative
- CD22 positive
- CDK4 positive
- CEACAM5 positive
- CLDN6 positive
- COL1A1 positive
- COL1A2 positive
- DMD positive
- Del(17p) negative
- EBV DNA positive
- ENPP1 positive
- EPCAM positive
- ER or PR positive
- ER/PR positive
- FGFR positive
- FOXO1 fusion negative
- FVIII positive
- GBA positive
- GLA positive
- GRN positive
- HBB mutation positive
- HBB positive
- HBV DNA negative
- HEXA positive
- HEXB positive
- HPV16 positive
- HR negative
- HRD positive
- HTT positive
- HbE positive
- HbSS positive
- IGHV negative
- IGHV positive
- KMT2A positive
- Ki-67 negative
- Ki67 positive
- MECP2 positive
- MMRp positive
- MSI negative
- MSS negative
- MYC negative
- NF1 negative
- NY-ESO-1 positive
- PDE6A positive
- PDE6B positive
- PH positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PTCH1 positive
- PTEN negative
- RAF positive
- SMARCB1 negative
- SMARCB1 positive
- SMN1 positive
- SPINK5 positive
- STK11 positive
- TET2 positive
- TTR negative
- UBE3A positive
- UGT1A1 negative
- ZnT8 positive
- anti-AChR positive
- anti-MuSK positive
- anti-PLA2R positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Allogeneic Hematopoietic Cell Transplantation
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
- Any Treatment Intervention Resulting in Improvement in Fatigue and Physical Function
- Any Treatment for Pancreatic Cancer
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
6641 trials
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing radiation therapy alone to radiation therapy with lymph node dissection in treating breast cancer patients who have already had chemotherapy and surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests how well nivolumab works in treating patients with anal cancer after they've received other treatments. Nivolumab may help the body's immune system attack the cancer, and may prevent tumor cells from growing and spreading.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing nivolumab with or without ipilimumab to see if it can treat patients with squamous cell lung cancer that has come back after previous treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Breast Cancer trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares shorter chemo-immunotherapy without anthracyclines to usual chemo-immunotherapy to treat early-stage triple negative breast cancer. Drugs used to stop cancer cells from growing/dividing & kill them, plus an immunotherapy drug.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a combination of two drugs to see if they're better than one drug at preventing breast cancer from coming back in patients with high risk, HER2 positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test new targeted cancer therapies against standard of care therapy in order to find more effective treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if rituximab works better with or without stem cell transplant for mantle cell lymphoma in patients who are in first complete remission.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different chemotherapy combinations to treat triple negative breast cancer to see which is more effective.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 33 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing two types of chemotherapy drugs to see which is more effective in treating patients with residual triple negative basal-like breast cancer.
Efficacy & Safety Awards
Approved for 10 Other Conditions
No Placebo-Only Group
Pivotal Trial
Get notified when new Cutaneous Melanoma trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying nivolumab and ipilimumab to see how well they work with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50